The combination of GBM-Serum-EVs with Ad-sh-EVA1 was shown to reverse the promoting effect of GBM-Serum-EVs alone on TMZ resistance in GBM xenografts (Supplementary Fig. 1A–C). The gene discussed is MPZL2; the disease is glioblastoma.